WHO approves China’s Sinopharm COVID-19 vaccine for emergency use

WHO approves China’s Sinopharm COVID-19 vaccine for emergency use. Know more.

Created On: May 8, 2021 14:51 ISTModified On: May 8, 2021 14:51 IST

The World Health Organization (WHO) on May 7, 2021, approved China’s Sinopharm COVID-19 vaccine for emergency use. The Sinopharm vaccine will now be included in the UN-backed COVAX vaccine distribution scheme.

“This afternoon, WHO gave emergency use listing to Sinopharm Beijing’s COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy, and quality,” said WHO chief Tedros Adhanom Ghebreyesus during a press conference.

WHO has already given its approval for the Pfizer/BioNTech, AstraZeneca, Johnson and Johnson, and Moderna but gave its approval to Sinopharm, a two-dose vaccine, after quite a delay due to the unavailability of data.

WHO chief Tedros further informed that the Strategic Advisory Group of Experts on Immunisation (SAGE) has also reviewed the available data on the Sinopharm vaccine and recommends it to be administered to adults over 18 years two-dose schedule.

About the Sinopharm vaccine:

•The Sinopharm vaccine is produced by the Beijing Bio-Institute of Biological Products Co Ltd, a subsidiary of China National Biotec Group (CNBG). 

•It is a two-dose vaccine. It is easy to store and highly viable for low-resource settings.

•It is the first vaccine that comes along with a vial monitor that changes color when exposed to heat. 

•The efficacy rate for symptomatic cases has been estimated to be 79 per cent.

Take Weekly Tests on app for exam prep and compete with others. Download Current Affairs and GK app

एग्जाम की तैयारी के लिए ऐप पर वीकली टेस्ट लें और दूसरों के साथ प्रतिस्पर्धा करें। डाउनलोड करें करेंट अफेयर्स ऐप

Comment ()

Related Stories

Post Comment

5 + 5 =